Combined in silico and in vitro approaches identified the antipsychotic drug lurasidone and the antiviral drug elbasvir as SARS-CoV2 and HCoV-OC43 inhibitors
| Autor: | Mario Milani, Edoardo Schneider, Francesco Bonì, Irene Arduino, Manuela Donalisio, Rafaela Milan Bonotto, David Lembo, Alessandro Marcello, Eloise Mastrangelo |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2021 |
| Předmět: |
0301 basic medicine
viruses Drug repurposing medicine.disease_cause Virus Replication Coronavirus OC43 Human chemistry.chemical_compound Lurasidone Hydrochloride RNA polymerase Chlorocebus aethiops Coronavirus OC43 Coronavirus Tumor Imidazoles Drug repositioning Antiviral screening HCoV-OC43 In silico docking SARS-CoV2 Animals Antiviral Agents Benzofurans COVID-19 Cell Line Tumor Computer Simulation Fibroblasts Humans SARS-CoV-2 Vero Cells Drug Repositioning Research Paper medicine.drug Human Elbasvir medicine.drug_class In silico 030106 microbiology Biology Cell Line 03 medical and health sciences Virology medicine Lurasidone Pharmacology COVID-19 Drug Treatment 030104 developmental biology Viral replication chemistry Antiviral drug |
| Zdroj: | Antiviral research 189 (2021). doi:10.1016/j.antiviral.2021.105055 info:cnr-pdr/source/autori:Milani M.; Donalisio M.; Bonotto R.M.; Schneider E.; Arduino I.; Boni F.; Lembo D.; Marcello A.; Mastrangelo E./titolo:Combined in silico and in vitro approaches identified the antipsychotic drug lurasidone and the antiviral drug elbasvir as SARS-CoV2 and HCoV-OC43 inhibitors/doi:10.1016%2Fj.antiviral.2021.105055/rivista:Antiviral research (Print)/anno:2021/pagina_da:/pagina_a:/intervallo_pagine:/volume:189 Antiviral Research |
| DOI: | 10.1016/j.antiviral.2021.105055 |
| Popis: | The current emergency of the novel coronavirus SARS-CoV2 urged the need for broad-spectrum antiviral drugs as the first line of treatment. Coronaviruses are a large family of viruses that already challenged humanity in at least two other previous outbreaks and are likely to be a constant threat for the future. In this work we developed a pipeline based on in silico docking of known drugs on SARS-CoV1/2 RNA-dependent RNA polymerase combined with in vitro antiviral assays on both SARS-CoV2 and the common cold human coronavirus HCoV-OC43. Results showed that certain drugs displayed activity for both viruses at a similar inhibitory concentration, while others were specific. In particular, the antipsychotic drug lurasidone and the antiviral drug elbasvir showed promising activity in the low micromolar range against both viruses with good selectivity index. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|